Global Cell and Gene Therapy Market By Therapy Type (Cell Therapy and Gene Therapy), By Indication (Genetic Disorders, Cardiovascular Disorders, Neurological Disorders, Oncological Disorders, and Others), By End-User (Hospitals, Academic & Research Institutes, Cancer Care Centers, and Others), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

The global cell and gene therapy market size is expected to be worth around USD 10.7 Billion by 2022 from USD 78.0 Billion in 2032, growing at a CAGR of 22.6% during the forecast period from 2022 to 2032.

Cell therapy includes the transfer of cells with the appropriate cell therapy. Gene therapy includes the transfer of genetic material, generally in a carrier or vector, and the uptake of the gene into the appropriate cells of the body. Cell therapy helps to treat diseases by reestablishing or changing certain groups of cells or by consuming cells to carry a therapy through the body.

Gene therapy helps to treat diseases by substituting, inactivating, or introducing genes into cells in-vivo or in-vitro. Cell and gene therapies are a transformative novel classification of medicines whose whole perspective is beginning. Cell and gene therapy has recently developed from a hypothesis to a life-saving reality.

Driving Factors

Rising Public and Private Expenditure in Cell and Gene Therapy to Drive the Market Growth

The limited number of adoption, cell, and gene therapy companies are attracting rising public and private spending. Private equity and capital expenditure in life sciences has increased rapidly in the last few years. The market is mainly driven due to the exponential rise in the clinical pipeline and increasing regulatory approvals for advanced medicines.

In order to develop the production of cell and gene therapies, various new techniques are being launched. The increasing need for cutting-edge treatments has raised market competition among the participants. In addition, the growing prevalence of cardiovascular disorders is anticipated to propel the market growth. Further, better healthcare infrastructure and increasing healthcare expenditure are the significant factors driving the market growth.

Restraining Factors

High-Cost Related to Cell and Gene Therapy Hinder Market Growth

The difficulty of cells and genes and treatment, comparatively lower production volumes, and a large number of manual influences include present methods, and cell therapies are high-cost to produce. The development has many problems, including safety and efficiency problems, stringent regulatory frameworks, and high cost of cell and gene therapy, which restrict the market growth. In addition, lengthy procedures for conducting clinical studies are the primary factor hampering the market growth.

COVID-19 Impact Analysis

COVID-19 had a negative impact on the global cell and gene therapy market. Cell and gene therapy are life-changing treatments, but the pandemic has affected the market hard. A review expresses the disturbance’s amount and suggests actions to aid corporations to become stronger. Due to the outbreak of COVID-19, companies faced substantial complexities in the supply of materials, manufacturing, and logistics procedures.

COVID-19 caused disturbances to the overall activities of cell and gene therapies, from manufacturing to health technology assessment. The manufacture and delivery of treatments, research, and clinical development of cell and gene therapy have been interrupted by the COVID-19 crisis. Supply shortages have also caused problems.

By Product Analysis

Cell Therapy Segment to Witness Significant Growth

The global cell and gene therapy market is segmented into cell and gene therapy. The cell therapy segment accounted for the highest market revenue share of 54.3% in 2022. The potential applications of cell therapies in treating autoimmune diseases, cancers, and urinary problems propel cell therapy segments’ growth.

Additionally, the accessibility of spending for novel cell lines and rising organic and inorganic growth strategies by companies to drive their cell therapy manufacturing abilities are some of the factors that drive the segment’s growth. Cell therapy refers to placing novel, healthy cells into the body to exchange diseases or damaged ones, to moderate the purpose of the patient’s cell through the appearance of issues or the elimination of the disease.

The gene therapy segment dominated during the historical period and is estimated to hold the second-largest market share. Gene therapy is an arena of medication that focuses on changing cells’ genetic makeup to treat diseases or reverse them by repairing genetic material that has been damaged.

By Indication Analysis

The Oncological Disorders Segment Dominates the Market Growth of the Cell and Gene Therapy Market

Based on Indication, the global cell and gene therapy market is classified into genetic, cardiovascular, and neurological disorders. The oncological disorders segment accounted for the maximum market revenue share of 32% in 2022. Research and treatments in the biomedical areas of cell therapy and gene therapy. Both treatments have the capability to lower the underlying cause of hereditary disorders and achieve disease.

The genetic disorder segment is anticipated to witness the fastest growth rate during the forecast period. Owing to the factors such as the high incidence of genetic and chronic disease cases and the developing government activities to increase public information about genetic diagnosis and testing. Specialists are generating new methods for screening, analyzing, and treating patients for cardiac infections as they explore the genetic roots of heart and vascular illness.

By End-User Analysis

The Hospitals Segment Dominated the Cell and Gene Therapy Market

Based on the end-user, the global cell and gene therapy market is divided into hospitals, academic& research institutes, cancer care centers, and others.  Among these, the hospital segment registers the highest CAGR during the forecast period. This is because hospitals provide access to novel therapies. The cancer research centers segment registers a CAGR of 5.3% in the cell and gene therapy market.

Key Market Segments

By Therapy Type

• Cell Therapy
• Gene Therapy

By Indication

• Genetic Disorders
• Cardiovascular Disorders
• Neurological Disorders
• Oncological Disorders
• Other Indications

By End-User

• Hospitals
• Academic & Research Institutes
• Cancer Care Centers
• Other End-Users

Growth Opportunity

Manufacturing Cell and Gene Therapies

Manufacturing cell and gene therapies offer lucrative opportunities for the market. The accessibility of reimbursement policies is anticipated to create various opportunities for the market players operating in the market. Additionally, rapid technological advancements in cell and gene therapy provide opportunities for the market. Authorization for product approval offers a novel opportunity for the cell and gene therapy market. Most of the key players are focusing on new products to capitalize on significant market growth opportunities.

Latest Trends

Increasing Expenditure is the Global Trend in the Market

The cell and gene therapy market has invested in the private and public sectors. For R &D efforts and innovative therapies. The number of cell and gene therapy products in clinical development has been gradually increasing. This indicates that the increasing investments and interest in various therapies target several diseases, including genetic, cardiovascular, and oncological disorders.

Regional Analysis

North America Dominates the Global Cell and Gene Therapy Market During the Forecast Period

North America accounted for a significant cell and gene therapy market revenue share of 49.6% due to the increasing cancer incidence and rising research activity in cancer and stem cells. The primary factor driving the growth of the North America region is enhancement in the country, a large number of active clinical trials, and the increasing engagement of firms in gene and cell therapy development.

Attributable to the favorable regulatory environment, mainly in the U.S. The U.S. Food and Drug Administration has established a collaborative administrative technique for cell and gene therapy with direct and consistent support.

Europe holds the second-largest revenue share during the forecast period. Various brands of novel collaborative research and invention have been introduced across Europe. One of the undertakings is testing gene therapy utilizing viral vectors. This is projected to drive the market growth across Europe.

The market increase is expected to be aided by the European region’s developed infrastructure and skilled labor force. The Asia-Pacific market is anticipated to hold the maximum revenue share during the forecast period.

Key Regions

• North America
  • o The US
  • o Canada
  • o Mexico
• Western Europe
  • o Germany
  • o France
  • o The UK
  • o Spain
  • o Italy
  • o Portugal
  • o Ireland
  • o Austria
  • o Switzerland
  • o Benelux
  • o Nordic
  • o Rest of Western Europe
• Eastern Europe
  • o Russia
  • o Poland
  • o The Czech Republic
  • o Greece
  • o Rest of Eastern Europe
• APAC
  • o China
  • o Japan
  • o South Korea
  • o India
  • o Australia & New Zealand
  • o Indonesia
  • o Malaysia
  • o Philippines
  • o Singapore
  • o Thailand
  • o Vietnam
  • o Rest of APAC
• Latin America
  • o Brazil
  • o Colombia
  • o Chile
  • o Argentina
  • o Costa Rica
  • o Rest of Latin America

• Middle East & Africa
  • o Algeria
  • o Egypt
  • o Israel
  • o Kuwait
  • o Nigeria
  • o Saudi Arabia
  • o South Africa
  • o Turkey
  • o United Arab Emirates
  • o Rest of MEA

Key Players Analysis

The cell and gene therapy market is highly developed with the presence of many international market players operating in the market. Market players are focusing on facilities that provide an understanding of global cell and gene therapy market opportunities. Project launches are common strategies followed by major market players for future research.

A vital importance of planned partnerships along with end users and developing innovative products are critical development taken by companies to strengthen their market position. Some of the prominent key players in the cell and gene therapy market include GlaxoSmithKline plc, Novartis AG, Amgen Inc., Pfizer Inc., Thermo Fisher Scientific Inc., Biogen Inc., and other key players.

Top Key Players

• GalaxoSmithKline plc
• Novartis AG
• Amgen Inc.
• Bristol-Myers Squibb Company
• Spark Therapeutics
• Pfizer Inc.
• Biogen Inc.
• Thermo Fisher Scientific Inc.
• Other Key Players

Recent Development

• October 2022-Pfizer Inc. introduced that they have successfully purchased Biohaven Pharmaceuticals which is a migraine drug manufacturing corporation. By Pfizers’acquistions, they will capable to prevent migraine patients with more treatment substitutes.
• January 2021-Thermo Fisher Scientific Inc. achieved Henogen S.S. Novasep’s viral vector manufacturing business in Belgium, for approximately in millions. This achievement will rise its presence in the market.
• February 2020- Catalent Inc. introduced the achievement of MaSTher Cell Global, Inc., to strengthen its market portfolio in cell and gene therapy market.

Report Scope